DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

Information source: NorthShore University HealthSystem Research Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prostate Cancer

Intervention: Dutasteride (Drug); Placebo (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: NorthShore University HealthSystem Research Institute

Official(s) and/or principal investigator(s):
Daniel H Shevrin, MD, Principal Investigator, Affiliation: NorthShore University HealthSystem


The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).

Clinical Details

Official title: Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Level of U19 gene expression in tumor from prostate gland.

Secondary outcome: Determination of PSA doubling time during off-phase of treatment

Detailed description: We have shown in a murine model of treatment with intermittent androgen ablation therapy of prostate cancer that when dutasteride is given during the regrowth phase (off-phase) of intermittent therapy, that tumor growth is inhibited and that survival is improved. We have also shown that testosterone is a more potent inducer of certain tumor suppressor androgen response genes than dihydrotestosterone. In this murine model, we showed that use of a 5-alpha reductase inhibitor (dutasteride) resulted in significant hyperinduction of the U19 tumor suppressor androgen response gene during the regrowth phase of treatment. In the current clinical trial, we will determine if use of dutasteride in men with advanced prostate cancer during the off-phase of intermittent androgen ablation therapy will also result in hyperinduction of these tumor suppressor androgen response genes. Gene expression will be measured in tumor tissue obtained by prostate biopsies during the off-phase when the testosterone level has normalized. PSA levels will also be measured to determine the PSA doubling time during the off-phase to determine the effect of dutasteride on PSA kinetics.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.


Inclusion Criteria:

- Histologically proven prostate cancer

- Patients are hormone-naive

- Patients either to begin androgen ablation therapy with LHRH agonist or already

receiving therapy with LHRH agonist

- Advanced prostate cancer with either positive pelvic nodes or bone/visceral


- Must have an intact prostate (no previous surgery or XRT)

- ECOG performance status 0-2

- Recovery from any major infection or surgical procedure

- Signed informed consent

Exclusion Criteria:

- Known intolerance or allergy to dutasteride

- Concomitant chemotherapy, biologic therapy, or XRT to prostate

- Bilateral orchiectomy

- Prior malignancy within 5 years of registration

Locations and Contacts

Northwestern University Medical Center, Chicago, Illinois 60611, United States

University of Chicago Hospitals and Clinics, Chicago, Illinois 60637, United States

NorthShore University HealthSystem, Evanston, Illinois 60201, United States

Additional Information

Starting date: March 2007
Last updated: February 13, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017